JNJ 8-K notes Q3 2025 sales release and planned Orthopaedics split

Rhea-AI Filing Summary

Johnson & Johnson filed an 8-K announcing two updates. First, it issued a press release reporting sales and earnings for the third quarter ended September 28, 2025. Second, it announced its intent to separate the Company’s Orthopaedics business.

The filing notes the related exhibits: Exhibit 99.1 contains the Q3 2025 press release and Exhibit 99.2 provides unaudited comparative supplementary sales data and a condensed consolidated statement of earnings for the fiscal third quarter and nine months. Exhibit 99.3 contains the press release about the planned Orthopaedics separation. These disclosures were dated October 14, 2025.

Insights

Corporate actions analyst

JNJ reported Q3 results and plans to separate Orthopaedics.

Johnson & Johnson disclosed the issuance of its Q3 press release for the period ended September 28, 2025, along with supplementary sales and earnings schedules. It also announced an intent to separate its Orthopaedics business via a dedicated press release.

The combination of an earnings update with a potential portfolio action can be meaningful, but the excerpt provides no structure, timing, or financial terms for the separation. Actual effects on revenue mix, margins, or capital structure will depend on the contemplated transaction details.

Subsequent filings may provide mechanics, timing, and any pro forma financials for the Orthopaedics separation, enabling assessment of ongoing business composition and financial profile.

0000200406false00002004062025-10-142025-10-140000200406us-gaap:CommonStockMember2025-10-142025-10-140000200406jnj:A1.150NotesDueNovember2028Member2025-10-142025-10-140000200406jnj:A2.700NotesDueFebruary2029Member2025-10-142025-10-140000200406jnj:A3.20NotesDueNovember2032Member2025-10-142025-10-140000200406jnj:A3.050NotesDueFebruary2033Member2025-10-142025-10-140000200406jnj:A1.650NotesDue2035Member2025-10-142025-10-140000200406jnj:A3.350NotesDueNovember2036Member2025-10-142025-10-140000200406jnj:A3.350NotesDueFebruary2037Member2025-10-142025-10-140000200406jnj:A3.550NotesDueNovember2044Member2025-10-142025-10-140000200406jnj:A3.600NotesDueFebruary2045Member2025-10-142025-10-140000200406jnj:A3.700NotesDueFebruary2055Member2025-10-142025-10-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): 

October 14, 2025

Johnson & Johnson

(Exact name of registrant as specified in its charter)

New Jersey			1-3215			22-1024240
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey  08933 

(Address of Principal Executive Offices)

 (Zip Code) 

Registrant's telephone number, including area code:

732-524-0400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, Par Value $1.00			JNJ			New York Stock Exchange
1.150% Notes Due November 2028			JNJ28			New York Stock Exchange
2.700% Notes due February 2029			JNJ29B			New York Stock Exchange
3.200% Notes Due June 2032			JNJ32			New York Stock Exchange
3.050% Notes due February 2033			JNJ33B			New York Stock Exchange
1.650% Notes Due May 2035			JNJ35			New York Stock Exchange
3.350% Notes Due June 2036			JNJ36A			New York Stock Exchange
3.350% Notes due February 2037			JNJ37B			New York Stock Exchange
3.550% Notes Due June 2044			JNJ44			New York Stock Exchange
3.600% Notes due February 2045			JNJ45			New York Stock Exchange
3.700% Notes due February 2055			JNJ55			New York Stock Exchange

Item 2.02 Results of operations and financial condition

On October 14, 2025, Johnson & Johnson (the “Company”) issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the third quarter ended September 28, 2025.

Item 8.01 Other events

On October 14, 2025, the Company issued the attached press release (Exhibit 99.3) announcing its intent to separate the Company's Orthopaedics business.

Item 9.01 Financial statements and exhibits

(d)    Exhibits.

Exhibit No.						Description of Exhibit
99.1						Press Release dated October 14, 2025 for the period ended September 28, 2025
99.2						Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the fiscal third quarter and nine months
99.3						Press Release dated October 14, 2025
104						The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 14, 2025

			JOHNSON & JOHNSON
			(Registrant)
By:			/s/ Robert J. Decker, Jr.
			Robert J. Decker, Jr. Controller (Principal Accounting Officer)

FAQ

What did JNJ (JNJ) disclose in this 8-K?

It announced a Q3 press release on sales and earnings and its intent to separate the Orthopaedics business.

Which period do the Johnson & Johnson Q3 results cover?

The third quarter ended September 28, 2025.

What exhibits are included with the 8-K for JNJ?

99.1 Q3 press release; 99.2 unaudited supplementary sales data and condensed earnings; 99.3 press release on the Orthopaedics separation.

When were the JNJ press releases issued?

The press releases were issued on October 14, 2025.

What business does Johnson & Johnson plan to separate?

The Company announced its intent to separate its Orthopaedics business.

Does the filing include detailed terms of the Orthopaedics separation?

No detailed terms appear in the excerpt; the 8-K references a press release in Exhibit 99.3.